Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleCARDIOVASCULAR

Chronic Type IV Phosphodiesterase Inhibition Protects Glomerular Filtration Rate and Renal and Mesenteric Blood Flow in a Zymosan-Induced Model of Multiple Organ Dysfunction Syndrome Treated with Norepinephrine

Neal J. Thomas, Joseph A. Carcillo, William A. Herzer, Zaichuan Mi and Edwin K. Jackson
Journal of Pharmacology and Experimental Therapeutics January 2001, 296 (1) 168-174;
Neal J. Thomas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph A. Carcillo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William A. Herzer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zaichuan Mi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edwin K. Jackson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

To examine the effects of chronic type IV phosphodiesterase (PDE4) inhibition on renal function and renal and mesenteric vascular resistance and blood flow in a sublethal model of multiple organ dysfunction syndrome (MODS) we used a prospective, randomized, controlled laboratory animal study. Twenty-eight rats had mini-infusion pumps placed to deliver vehicle or PDE4 inhibition with Ro 20-1724 at doses of either 0.3 or 2.0 μg/kg/min. Simultaneously, MODS was induced by intraperitoneal injection of zymosan (0.25 mg/g). Mean arterial blood pressure, heart rate, renal blood flow, and superior mesenteric blood flow (SMABF) were measured at 48 h. Renal vascular resistance (RVR), superior mesenteric artery vascular resistance (SMAVR), and glomerular filtration rate were calculated. A dose-response effect of norepinephrine was also evaluated at 48 h. Chronic Ro 20-1724 treatment prevented norepinephrine-induced vasoconstriction in control rats. Inhibition of PDE4 with Ro 20-1724 (2.0 μg/kg/min) increased urinary cAMP, and attenuated the increase in RVR and SMAVR (p < 0.05) and the decrease in RBF and SMABF (p < 0.05) that occurred from zymosan and norepinephrine. Glomerular filtration rate was also preserved (p < 0.05), despite a reduction in blood pressure. Chronic PDE4 inhibition protects renal function and mesenteric perfusion during MODS by increasing cAMP in the presence and absence of catecholamines. Higher doses of PDE4 inhibition result in clinically tolerated decreases in mean arterial blood pressure, with improved end-organ function. Chronic PDE4 inhibition is protective, likely through cAMP-mediated attenuation of vasoconstriction.

Footnotes

  • Send reprint requests to: Neal J. Thomas, M.D., Department of Pediatric Critical Care Medicine, Pennsylvania State University College of Medicine, P.O. Box 850, Hershey, PA 17033. E-mail: nthomas{at}psu.edu

  • ↵1 Current address: Department of Pediatrics, Division of Pediatric Critical Care Medicine, The Pennsylvania State University College of Medicine, Hershey, PA 17033.

  • This study was funded in part by Department of Anesthesia Seed Grant, University of Pittsburgh, 3 M01RR00056GCRC, and National Institutes of Health Grants HL55314 and HL35909. This work was presented in part at The Society of Critical Care Medicine's 27th Educational and Scientific Symposium, San Antonio, TX, February 4–8, 1998.

  • Abbreviations:
    PDE
    phosphodiesterase
    PDE4
    type IV phosphodiesterase
    MODS
    multiple organ dysfunction syndrome
    PE
    polyethylene
    MABP
    mean arterial blood pressure
    HR
    heart rate
    RBF
    renal blood flow
    MBF
    mesenteric blood flow
    GFR
    glomerular filtration rate
    RVR
    renal vascular resistance
    SMAVR
    superior mesenteric artery vascular resistance
    SMABF
    superior mesenteric blood flow
    • Received June 26, 2000.
    • Accepted September 6, 2000.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 296 (1)
Journal of Pharmacology and Experimental Therapeutics
Vol. 296, Issue 1
1 Jan 2001
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Chronic Type IV Phosphodiesterase Inhibition Protects Glomerular Filtration Rate and Renal and Mesenteric Blood Flow in a Zymosan-Induced Model of Multiple Organ Dysfunction Syndrome Treated with Norepinephrine
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleCARDIOVASCULAR

Chronic Type IV Phosphodiesterase Inhibition Protects Glomerular Filtration Rate and Renal and Mesenteric Blood Flow in a Zymosan-Induced Model of Multiple Organ Dysfunction Syndrome Treated with Norepinephrine

Neal J. Thomas, Joseph A. Carcillo, William A. Herzer, Zaichuan Mi and Edwin K. Jackson
Journal of Pharmacology and Experimental Therapeutics January 1, 2001, 296 (1) 168-174;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleCARDIOVASCULAR

Chronic Type IV Phosphodiesterase Inhibition Protects Glomerular Filtration Rate and Renal and Mesenteric Blood Flow in a Zymosan-Induced Model of Multiple Organ Dysfunction Syndrome Treated with Norepinephrine

Neal J. Thomas, Joseph A. Carcillo, William A. Herzer, Zaichuan Mi and Edwin K. Jackson
Journal of Pharmacology and Experimental Therapeutics January 1, 2001, 296 (1) 168-174;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Optimized S-nitrosohemoglobin synthesis in red blood cells
  • High-Salt Diet Upregulates CaSR Expression and Signaling
  • L-Arginine improves post-infarction physical function
Show more Cardiovascular

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics